Published Date: 23 Apr 2023
The treatment of chronic thromboembolic pulmonary hypertension with balloon pulmonary angioplasty has an evolving safety profile over the years, from 2013 to 2022, as revealed by an analysis of more than two dozen studies.
Read Full NewsAs part of NeurologyLive®'s Year in Review 2025, we've compiled some notable trials that began in 2025.
The director of the Pediatric Epilepsy Center at UCSF reviewed recently presented interim phase 1/2 data for ETX101, a one-time AAV9 gene regulation therapy aiming to increase SCN1A expression in inhibitory interneurons in Dravet syndrome.
As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews regarding multiple sclerosis in 2025.
Hidradenitis Suppurativa in 2025: Year in Review
1.
Unified Neuro/Psych Residency Program: New Proposal.
2.
Q&A: Researchers discuss identifying potential new protein targets for melanoma therapeutics
3.
What is Mohs micrographic surgery? 8 FAQs about Mohs
4.
As compared to proton therapy, proton therapy is very effective in treating esophageal cancer.
5.
Simultaneously targeting lysosomal enzyme and KRAS-MAPK pathway eradicates pancreatic tumors in preclinical models
1.
Unlocking the Secrets of Ringed Sideroblasts: A New Frontier in Hematology
2.
The Unseen Threat: Uncovering the Risks of Pancoast Tumor
3.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
4.
Potential of Device-Assisted Therapy in Non-Muscle-Invasive Bladder Cancer
5.
Revolutionizing Cancer Treatment: Harnessing the Power of AI in Histopathology
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Nimotozumab Plus Chemo-radiotherapy v/s Placebo Plus Chemo-radiotherapy in Locally Advanced Nasopharyngeal Carcinoma
2.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III
3.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
4.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
5.
Efficient Management of First line ALK-rearranged NSCLC
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation